Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02593175 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | completed | — | 327 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT03860961 | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | completed | N/A | 550 | NRG OncologyOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT06106282 | Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) | completed | — | 105 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT00183885 | A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 76 | University of Southern CaliforniaOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours(ROLo) | completed | Phase 2 | 33 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03036488 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | completed | Phase 3 | 1,174 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Oct 29, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04408105 | Survey Study on Barrett's Esophagus Screening(SCREEN-BE) | completed | — | 725 | University of Colorado, DenverOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04049227 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | completed | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 684 | BeiGeneINDUSTRY | 11 | Oct 14, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03404960 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy(Parpvax) | completed | Phase 1 / Phase 2 | 104 | University of PennsylvaniaOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04169711 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | completed | Phase 1 | 26 | Arrowhead PharmaceuticalsINDUSTRY | 1 | Oct 9, 2025 | clinicaltrials |
| NCT06572800 | Tka Assay for CDK4/6i | completed | N/A | 34 | Yale UniversityOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05599334 | A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib(NEAR) | completed | — | 111 | Pierre Fabre MedicamentINDUSTRY | 5 | Oct 6, 2025 | clinicaltrials |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma(SOMAPROTECT01) | completed | Phase 3 | 179 | Hospices Civils de LyonOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03460483 | Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care(OPTEC) | completed | N/A | 1,001 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05051475 | Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus(RATE) | completed | N/A | 62 | Centre of Postgraduate Medical EducationOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02738294 | Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB | completed | N/A | 211 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01935934 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 2 | Oct 1, 2025 | clinicaltrials |
| NCT03044587 | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer(NIFE) | completed | Phase 2 | 93 | AIO-Studien-gGmbHOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | completed | Phase 2 | 147 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03062358 | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Sep 30, 2025 | clinicaltrials |
| NCT04257448 | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer(SEPION) | completed | Phase 1 / Phase 2 | 75 | GWT-TUD GmbHOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03516812 | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 36 | University of WashingtonOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06230328 | Brazilian Reality of Hepatocellular Carcinoma(BRA-HEP) | completed | — | 300 | AstraZenecaINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT03075423 | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | completed | Phase 2 | 316 | Goethe UniversityOTHER | 7 | Sep 26, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT05351983 | Patient-derived Organoids Drug Screen in Pancreatic Cancer | completed | N/A | 60 | Prof. Dr. med. Dres. h.c. Jan Schmidt, MMEOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04664829 | The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC | completed | Phase 1 | 12 | National Cancer Centre, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02186470 | Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer | completed | N/A | 22 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04487067 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista(AMETHISTA) | completed | Phase 3 | 152 | Hoffmann-La RocheINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06358001 | EchoTip AcuCore Post-Market Clinical Study | completed | — | 183 | Cook Research IncorporatedINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04118062 | Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) | completed | N/A | 128 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07181954 | CT-based Radiomics for Prediction of MIT Family Translocation Kidney Cancer: a Multicenter, Retrospective Clinical Study | completed | — | 746 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07184424 | Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC(Lenalidomide) | completed | N/A | 24 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT01841749 | Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast(CINNAMOME) | completed | — | 228 | Institut BergoniéOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07167147 | Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery(STARS) | completed | — | 7,259 | Chang Gung Memorial HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 6, 2025source: clinicaltrials